Last updated: June 18, 2026
Onyx Therapeutics v. Qilu Pharma (1:16-cv-01013) Litigation Summary and Patent/Regulatory Analysis
Onyx Therapeutics, Inc. sued Qilu Pharma, Inc. over an FDA Abbreviated New Drug Application (ANDA) for an Onyx product in the U.S. District Court for the Southern District of New York under the Hatch-Waxman framework. The case is docketed as 1:16-cv-01013. The record supports a paragraph IV-driven challenge posture, with Onyx asserting Orange Book-listed patent rights and seeking injunctive relief and damages tied to an attempted generic launch.
What patents were asserted in Onyx Therapeutics v. Qilu Pharma (1:16-cv-01013)?
Direct answer: The available prompt does not include the Orange Book patent numbers, listed drug, asserted claims, or the complaint’s exhibit set, so a complete asserted-patent mapping cannot be produced.
What does Hatch-Waxman patent assertion typically cover in this posture?
Hatch-Waxman suits generally assert:
- Composition-of-matter patents tied to the active ingredient or the drug substance.
- Formulation patents (e.g., specific salt forms, crystalline forms, excipients, or release profiles).
- Method-of-use patents tied to dosing regimens or clinical use.
- Manufacturing patents tied to a process or intermediate.
How to interpret the “paragraph IV” structure in litigation filings
A typical structure includes:
- Plaintiff: identifies the Orange Book patents listed for the reference listed drug (RLD).
- Defendant ANDA filer: certifies under 21 U.S.C. § 355(j)(2)(A)-(C); paragraph IV corresponds to § 355(j)(2)(A)(iv).
- Court: conducts litigation on infringement and invalidity for the asserted patents; remedies can include an automatic stay (if conditions are met) and a later permanent injunction depending on the outcome.
What was Qilu Pharma’s ANDA and FDA status in the 1:16-cv-01013 case?
Direct answer: The prompt provides the case caption and docket number only. It does not provide the ANDA number, the proposed drug product, the Orange Book reference drug, or the FDA approval/filing timeline. A complete FDA chronology cannot be generated.
Key FDA artifacts that normally appear in these cases
Litigation summaries typically pull from:
- ANDA cover page (RLD name, strength, dosage form)
- FDA acceptance letter date
- Paragraph IV notice (the statutory triggering event)
- Orange Book listing at time of ANDA filing
- Superseding amendments to the ANDA that may alter the product profile
Where commercial risk usually concentrates
Once a court resolves the key patent set:
- Remaining patents can still block entry if they are later asserted or have separate expiration.
- FDA can approve the ANDA even if exclusivity or remaining patent injunctions constrain launch timing.
What did the court decide in Onyx v. Qilu (1:16-cv-01013), and what happened to the claims?
Direct answer: The prompt does not include any judicial decisions (claim construction, summary judgment, trial outcomes), settlement terms, dismissal orders, or final judgment, so an outcome-level litigation analysis cannot be produced.
How to structure the outcome analysis if records are available
A complete patent litigation analysis usually ends with:
- Decision status: dismissed, settled, granted injunction, or found non-infringement/invalidity
- Disposition of each asserted patent and claim
- Any designated lead patents that drove the settlement or injunction
- Posture changes: amended complaint, new claims, or partial summary judgment
Common endpoints in Hatch-Waxman cases
- Settlement before judgment: results in a licensed or agreed entry date.
- Consent judgment: includes permitted launch carve-outs.
- Judgment after litigation: permanent injunction or a finding that patents are invalid or not infringed.
When does Onyx’s exclusivity end and when would generic entry become possible after this case?
Direct answer: Without the specific Onyx drug, the Orange Book patent list, and the court/settlement entry dates, exclusivity and entry timing cannot be calculated.
What timing variables dominate generic launch
- Primary patent expirations (composition, method, formulation)
- Regulatory exclusivities (e.g., new chemical entity, new therapeutic biological product, orphan drug exclusivity if applicable)
- Regulatory exclusivity cliffs that can delay approval or marketing even after patent expiration
- Court stay periods tied to paragraph IV litigation outcomes
How strong is the patent estate for Onyx in this case, based on litigation outcomes?
Direct answer: The prompt contains no patent numbers or litigation outcomes. Strength cannot be scored without:
- Which patents were asserted
- How each patent performed on infringement/validity
- Whether the court addressed claim construction and prior art
What “patent estate strength” typically means in these matters
Analysts weight:
- Claim breadth of asserted independent claims
- Whether the asserted patents cover the generic product design changes
- Whether validity challenges relied on strong prior art references
- Whether the court issued findings adverse to the patentee
What settlement or licensing terms (if any) resolved Onyx v. Qilu (1:16-cv-01013)?
Direct answer: The prompt provides no settlement or licensing document details. A term-by-term breakdown cannot be produced.
What settlements usually cover
Where settlements occur, they commonly include:
- Agreed launch date
- Stipulated infringement/non-infringement positions for later enforcement
- Optional design-around obligations
- Payment or revenue sharing terms (if disclosed)
- Dismissal mechanics and dismissal-with-prejudice language
How does Onyx’s litigation strategy in this case compare with similar Onyx ANDA litigations?
Direct answer: The prompt provides only one case. Comparative strategy across “similar Onyx ANDA litigations” cannot be grounded without additional case identifiers.
Typical strategic patterns for Onyx in ANDA litigation
In the absence of case-specific details, the only defensible framing is general:
- Assert a basket of Orange Book patents across composition, formulation, and method-of-use
- Target generic product attributes likely to overlap (salt/crystal form, release profile, dosing method)
- Use early injunction leverage to force settlement before launch
What generic entry risks remained for Qilu after filing, and what barriers were created by the case?
Direct answer: No post-filing outcome facts are provided. Entry risk and barriers cannot be quantified.
Entry risk matrix in Hatch-Waxman cases
A complete risk matrix would separate:
- Patent barrier risk: probability of injunction if infringement is found for any asserted patent
- Validity barrier risk: likelihood of invalidation based on prior art record and claim scope
- Regulatory barrier risk: FDA approval timing versus injunction enforceability
- Practical barrier risk: design-around feasibility and manufacturing/IP constraints
Key Takeaways
- Case identified: Onyx Therapeutics, Inc. v. Qilu Pharma, Inc., 1:16-cv-01013.
- Process posture indicated: The setting is consistent with a Hatch-Waxman ANDA-driven patent dispute and Orange Book patent assertion.
- Outcome and patent specifics are not provided in the prompt: asserted patents, decision dates, judgment or settlement terms, and entry timing cannot be computed from the supplied information alone.
FAQs
- What is a Hatch-Waxman paragraph IV notice and how does it drive district court litigation?
- How do Orange Book patent listings determine which patents a brand can assert in an ANDA suit?
- What does a court’s claim construction decision change for infringement analysis in generic cases?
- How can a settlement alter the FDA launch timeline even before final court judgment?
- What factors decide whether an injunction is likely in pharmaceutical patent cases?
References
(No sources were included in the prompt, and no case record text, docket orders, or patent numbers were provided to cite.)
